Trial Profile
An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Pimurutamab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Henlius Biotech
- 06 Jun 2023 Results evaluating safety of HLX-007 in combination with chemotherapy in patients with advanced solid tumours were presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 26 May 2023 Results presented in a Shanghai Henlius Biotech media release.
- 26 May 2023 According to a Shanghai Henlius Biotech media release, results from this study were released as online abstract by 2023 American Society of Clinical Oncology (ASCO) Annual Meeting for the first time.